Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

peptide drug conjugate OPD5

A peptide-drug conjugate (PDC) composed of a peptide conjugated, via an aminopeptidase-targeting linkage, to an as of yet undisclosed alkylating agent, with potential antineoplastic activity. Upon administration, PDC OPD5 is hydrolyzed by peptidases to release the alkylating agent, thereby allowing for specific accumulation of the agent in aminopeptidase-positive tumor cells. This may result in the inhibition of DNA and/or RNA synthesis and the induction of apoptosis, thereby inhibiting tumor cell proliferation. Peptidases are overexpressed by certain cancer cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	PDC OPD5
Code name:	OPD 5 OPD-5 OPD5

peptide drug conjugate OPD5

Search NCI's Drug Dictionary